Peringatan Keamanan

Side effects include blurred vision or change in near or distant vision and eye pain.
LD50: 174 mcg/kg in rats. (MSDS)

Echothiophate

DB01057

small molecule approved

Deskripsi

A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.

Struktur Molekul 2D

Berat 256.323
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

This ophthalmic medication may be systemically absorbed.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

26 Data
Dipyridamole The therapeutic efficacy of Echothiophate can be decreased when used in combination with Dipyridamole.
Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Echothiophate.
Pitolisant Echothiophate may increase the QTc-prolonging activities of Pitolisant.
Lefamulin Lefamulin may increase the QTc-prolonging activities of Echothiophate.
Hydroxyzine The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Hydroxyzine.
Ziprasidone The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Ziprasidone.
Haloperidol The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Haloperidol.
Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Echothiophate.
Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Echothiophate.
Fexinidazole The risk or severity of adverse effects can be increased when Echothiophate is combined with Fexinidazole.
Clozapine The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Clozapine.
Glasdegib The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Glasdegib.
Vilanterol The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Echothiophate.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Echothiophate.
Quizartinib The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Quizartinib.
Citalopram The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Citalopram.
Pimavanserin The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Pimavanserin.
Gepirone The risk or severity of QTc prolongation can be increased when Gepirone is combined with Echothiophate.
Etrasimod The risk or severity of QTc prolongation and torsade de pointes can be increased when Etrasimod is combined with Echothiophate.
Bedaquiline The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Bedaquiline.
Encorafenib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Echothiophate.
Givinostat The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Givinostat.
Inotuzumab ozogamicin The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Inotuzumab ozogamicin.
Mavorixafor The risk or severity of QTc prolongation can be increased when Mavorixafor is combined with Echothiophate.
Ribociclib The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Echothiophate.
Revumenib The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Revumenib.

Target Protein

Cholinesterase BCHE
Acetylcholinesterase ACHE

Referensi & Sumber

Synthesis reference: Fitch, H.M.; U.S. Patent 2,911,430; November 3, 1959; assigned to Campbell Pharmaceuticals, Inc.
Artikel (PubMed)
  • PMID: 7166393
    Reddy RH: Echothiophate iodide: its use in accommodative esotropia (high Ac/A ratio). Indian J Ophthalmol. 1982 Jul;30(4):225.
  • PMID: 20673046
    Schmidt KG, Horowitz Y, Buckman G, Segev E, Levinger E, Geyer O: Lowering of IOP by echothiophate iodide in pseudophakic eyes with glaucoma. Curr Eye Res. 2010 Aug;35(8):698-702. doi: 10.3109/02713681003794076.

Contoh Produk & Brand

Produk: 14 • International brands: 1
Produk
  • Phospholine Iodide
    Powder, for solution • 6.25 mg/5mL • Ophthalmic • US • Approved
  • Phospholine Iodide
    Powder, for solution • 6.25 mg/5mL • Ophthalmic • US • Approved
  • Phospholine Iodide
    Solution • 1.5 mg/5mL • Ophthalmic • US • Approved
  • Phospholine Iodide
    Solution • 3 mg/5mL • Ophthalmic • US • Approved
  • Phospholine Iodide
    Solution • 12.5 mg/5mL • Ophthalmic • US • Approved
  • Phospholine Iodide
    Kit • 6.25 mg/5mL • Ophthalmic • US • Approved
  • Phospholine Iodide - Liq Pws 3mg/5ml
    Liquid; Powder, for solution • 3 mg / 5 mL • Ophthalmic • Canada • Approved
  • Phospholine Iodide - Pws 12.5mg/5ml
    Powder, for solution • 12.5 mg / 5 mL • Ophthalmic • Canada • Approved
Menampilkan 8 dari 14 produk.
International Brands
  • Echodide — Alcon

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul